T-cell-mediated lysis of B cells induced by a CD19xCD3 bispecific single-chain antibody is perforin dependent and death receptor independent

Cancer Immunology, Immunotherapy

Volumn 53, Issue 7, 2004, Pages 625-632

  Gruen, Michael ^a,b,d   Bommert, Kurt ^b   Bargou, Ralf C ^a,b,c  

^a HUMBOLDT UNIVERSITY   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^c HELIOS KLINIKUM BERLIN BUCH   (Germany)

^d FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

B NHL; Bispecific antibody; Immunotherapy; Perforin; T cell

Indexed keywords

FAS LIGAND; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ARTICLE; B LYMPHOCYTE; CELL DEATH; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXICITY; EXOCYTOSIS; GOLGI COMPLEX; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PRIORITY JOURNAL; RAJI CELL; T LYMPHOCYTE; UPREGULATION;

ANTIBODIES, BISPECIFIC; ANTIGENS, CD19; ANTIGENS, CD3; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; B-LYMPHOCYTES; CARRIER PROTEINS; CASP8 AND FADD-LIKE APOPTOSIS REGULATING PROTEIN; CYTOPLASMIC GRANULES; CYTOTOXICITY, IMMUNOLOGIC; EXOCYTOSIS; FAS LIGAND PROTEIN; HUMANS; IMMUNOTHERAPY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LIGANDS; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; PORE FORMING CYTOTOXIC PROTEINS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 3042802506     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-003-0496-2     Document Type: Article

References (29)

1. Landis SH, Murray T, Bolden S, Wingo PA (1999) Cancer statistics, 1999. CA Cancer J Clin 49:8
2. Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, Emmerich B (2001) Rituximab in the treatment of patients with B-cell chronic lymphocytic leukemia. Blood 98:1326
3. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A (1999) Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood 94:2217
4. van Spriel AB, van Ojik HH, van De Winkel JG (2000) Immunotherapeutic perspective for bispecific antibodies. Immunol Today 21:391
5. Bauer S, Renner C, Juwana J-P, Held G, Ohnesorge S, Gerlach K, Pfreundschuh M (1999) Immunotherapy of human tumors with T-cell-activating bispecific antibodies: stimulation of cytotoxic pathways in vivo. Cancer Res 59:1961
6. Renner C, Held G, Ohnesorge S, Bauer S, Gerlach K, Pfitzenmeier J-P, Pfreundschuh M (1997) Role of naive and memory T cells in tumor cell lysis mediated by bi-specific antibodies. Immunobiol 197:122
7. Renner C, Held G, Ohnesorge S, Bauer S, Gerlach K, Pfitzenmeier J-P, Pfreundschuh M (1997) Role of perforin, granzymes and the proliferative state of the target cells in apoptosis and necrosis mediated by bispecific-antibody- activated cytotoxic T cells. Cancer Immunol Immunother 44:70
8. Manzke O, Berthold F, Huebel K, Tesch H, Diehl V, Bohlen H (1999) CD3xCD19 bispecific antibodies and CD28 bivalent antibodies enhance T-cell reactivity against autologous leukemic cells in pediatric B-ALL bone marrow. Int J Cancer 80:715
9. Zeidler R, Mayer A, Gires O, Schmitt B, Mack B, Lindhofer H, Wollenberg B, Walz A (2001) TNFα contributes to the antitumor activity of a bispecific, trifunctional antibody. Anticancer Res 21:3499
10. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmüller G, Bargou RC, Baeuerle PA (2002) Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 100:690
11. Dreier T, Baeuerle PA, Fichtner I, Grün M, Schlereth B, Lorenczewski G, Kufer P, Lutterbüse R, Riethmüller G, Gjorstrup P, Bargou RC (2003) T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J Immunol 170:4397
12. Löffler A, Kufer P, Lutterbüse R, Zettl F, Daniel PT, Schwenkenbecher JM, Riethmüller G, Dörken B, Bargou RC (2000) A recombinant bispecific single-chain antibody, CD19xCD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood 95:2098
13. Löffler A, Grün M, Wuchter C, Schriever F, Kufer P, Dreier T, Hanakam F, Baeuerle PA, Bommert K, Karawajew L, Dörken B, Bargou RC (2003) Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 17:900
14. Russell JH, Ley TJ (2002) Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 20:323
15. Shi L, Kraut RP, Aebersold R, Greenberg AH (1992) A natural killer cell granule protein that induces DNA fragmentation and apoptosis. J Exp Med 175:553
16. Froelich CJ, Orth K, Turbov J, Seth P, Gottlieb R, Babior B, Shah GM, Bleackley RC, Dixit VM, Hanna W (1996) New paradigm for lymphocyte granule-mediated cytotoxicity. Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis. J Biol Chem 271:29073
17. Krammer PH (2000) CD95's deadly mission in the immune system. Nature 407:789
18. Kataoka T, Shinohara N, Takayama H, Takaku K, Kondo S, Yonehara S, Nagai K (1996) Concanamycin A, a powerful tool for characterization and estimation of contribution of perforin-and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 156:3678
19. Kayagaki N, Yamaguchi N, Nakayama M, Kawasaki A, Akiba H, Okumura K, Yagita H (1999) Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J Immunol 162:2639
20. Chatterjee D, Schmitz I, Krueger A, Yeung K, Kirchhoff S, Krammer PH, Peter ME, Wyche JH, Pantazis P (2001) Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short). Cancer Res 61:7148
21. Cinatl J Jr, Blaheta R, Bittoova M, Scholz M, Marraf S, Vogel JU, Cinatl J, Doerr HW (2000) Decreased neutrophil adhesion to human cytomegalovirus- infected retinal pigment epithelial cells is mediated by virus-induced up-regulation of Fas ligand independent of neutrophil apoptosis. J Immunol 165:4405
22. Trapani JA, Davis J, Sutton VR, Smyth MJ (2000) Proapoptotic functions of cytotoxic lymphocyte granule constitutents in vitro and in vivo. Curr Op Immunol 12:323
23. Hennino A, Berard M, Casamayor-Palleja M, Krammer PH, Defrance T (2000) Regulation of the Fas death pathway by FLICE-inhibitory protein in primary human B cells. J Immunol 165:3023
24. Di Somma MM, Somma F, Montani MS, Mangiacasale R, Cundari E, Piccolella E (1999) TCR engagement regulates differential responsiveness of human memory T cells to Fas (CD95)-mediated apoptosis. J Immunol 162:3851
25. De Gast GC, Haagen I-A, van Houten AA, Klein SC, Duits AJ, de Weger RA, Vroom TM, Clark MR, Phillips J, van Dijk AJG, de Lau WBM, Bast BJEG (1995) CD8 T cell activation after intravenous administration of CD3xCD19 bispecific antibody in patients with non-Hodgkin lymphoma. Cancer Immunol Immunother 40:390
26. 2. J Natl Cancer Inst 85:1003
27. Mack M, Gruber R, Schmidt S, Riethmüller G, Kufer P (1997) Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity. J Immunol 158:3965
28. Rothstein TL (2000) Inducible resistance to Fas-mediated apoptosis in B cells. Cell Res 10:245
29. Yasukawa M, Ohminami H, Arai J, Kasahara Y, Ishida Y, Fujita S (2000) Granule exocytosis, and not the fas/fas ligand system, is the main pathway of cytotoxicity mediated by allo-antigen-specific CD4(+) as well as CD8(+) cytotoxic T lymphocytes in humans. Blood 95:2352